Is platinum‑based doublet chemotherapy the standard first‑line therapy for advanced non‑small cell lung cancer (NSCLC) with a KRAS mutation and low programmed death‑ligand 1 (PD‑L1) expression, and what are its effects on the tumor microenvironment, including tumor vasculature, extracellular matrix, and tumor progression?

Platinum-Doublet Chemotherapy is NOT the Standard of Care for KRAS-Mutated NSCLC with Low PD-L1

For advanced NSCLC with KRAS mutation and low PD-L1 expression, platinum-doublet chemotherapy combined with PD-1/PD-L1 inhibitors is the current standard of care, NOT chemotherapy alone 1. The addition of immunotherapy to chemotherapy significantly improves outcomes compared to chemotherapy alone, even in patients with low PD-L1 expression.

Current Standard Treatment Algorithm

For KRAS-Mutated NSCLC with Low PD-L1 (<50%) and Good Performance Status (PS 0-1):

First-line options include:

• Non-squamous histology: Pembrolizumab + pemetrexed + platinum 1, atezolizumab + bevacizumab + paclitaxel + carboplatin 1, or nivolumab + ipilimumab + 2 cycles of chemotherapy 1

• Squamous histology: Pembrolizumab + carboplatin + (nab)-paclitaxel 1 or nivolumab + ipilimumab + 2 cycles of chemotherapy 1

The key principle: Combinations of platinum-based chemotherapy and anti-PD-(L)1 inhibitors are preferred over platinum-based chemotherapy alone 1.

Important Context for KRAS Mutations:

The 2024 NCCN guidelines specifically note that patients with KRAS mutations are likely to derive benefit from immunotherapy-based regimens in the first-line setting 2. There is a positive association between PFS and PD-L1 expression in KRAS-mutated patients receiving immunotherapy 2. However, targeted therapies (sotorasib, adagrasib) are NOT recommended as first-line treatment for KRAS G12C mutations 2—these are reserved for subsequent lines after progression on immunotherapy-based regimens.

Effects on Tumor Microenvironment

Your question about chemotherapy's effects on the tumor microenvironment is clinically relevant, as these effects actually provide the mechanistic rationale for combining chemotherapy with immunotherapy:

Positive Immunomodulatory Effects:

Platinum-based chemotherapy exerts several beneficial effects on the tumor microenvironment that enhance immunotherapy efficacy 3:

• Increases tumor immunogenicity through immunogenic cell death (ICD), releasing tumor antigens and damage-associated molecular patterns
• Enhances T-cell infiltration into tumors by modulating the tumor vasculature and extracellular matrix
• Depletes immunosuppressive cells including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs)
• Activates dendritic cells and improves antigen presentation
• Stimulates cytotoxic T lymphocyte (CTL) activity through cGAS-STING pathway activation

Negative Immunomodulatory Effects (The Rationale for Adding Immunotherapy):

Critically, platinum-based chemotherapy upregulates PD-L1 expression on tumor cells 4. In a study of 86 NSCLC patients receiving platinum-based neoadjuvant chemotherapy, 30.2% of initially PD-L1-negative tumors became PD-L1-positive after chemotherapy 4. This upregulation represents an adaptive immune resistance mechanism that can be counteracted by PD-1/PD-L1 inhibitors 3, 4.

This PD-L1 upregulation after chemotherapy was associated with:

• Lack of response to chemotherapy alone 4
• Tendency toward shorter survival when chemotherapy was used without immunotherapy 4

Clinical Implications:

The tumor microenvironment changes induced by chemotherapy create a window of opportunity where adding PD-1/PD-L1 inhibitors can:

1. Block the chemotherapy-induced PD-L1 upregulation
2. Capitalize on the enhanced tumor immunogenicity
3. Prevent immune escape mechanisms

This synergistic mechanism explains why chemoimmunotherapy combinations consistently outperform chemotherapy alone in clinical trials 1, 3.

Prognostic Considerations for KRAS Mutations

KRAS mutations confer a mildly negative prognostic impact when treated with platinum-based chemotherapy alone. In a study of 247 EGFR wild-type patients, those with KRAS mutations had median OS of 10.6 months versus 14.3 months for KRAS wild-type (HR=1.41, p=0.032) 5. This further supports the use of combination chemoimmunotherapy rather than chemotherapy alone.

Recent real-world data demonstrates that first-line PD-1/PD-L1 immunotherapy shows numerically better clinical efficacy than traditional platinum-doublet chemotherapy in KRAS-mutated NSCLC, with median PFS of 7.9 months versus 6.0 months (p=0.030) 6. PD-L1 expression serves as an independent protective factor for PFS in these patients 6.

Common Pitfalls to Avoid:

1. Do not use chemotherapy alone in fit patients (PS 0-1) with KRAS-mutated NSCLC, regardless of PD-L1 level—this is outdated practice
2. Do not use KRAS G12C inhibitors (sotorasib/adagrasib) first-line—reserve these for second-line or later after progression on chemoimmunotherapy 2
3. Do not assume low PD-L1 means immunotherapy won't work—the combination with chemotherapy overcomes low PD-L1 expression 1
4. Do not continue immunotherapy beyond 2 years in most cases due to toxicity risk, particularly with nivolumab-ipilimumab regimens 1